CD274 and urothelial carcinoma: A specific response score (PD-L1 or CPS) was determined in urothelial carcinoma patients treated with Pembrolizumab: his was defined as the percentage of PD-L1 expression in tumor and infiltrating immune cells relative to the total number of tumor cells, with positive markers scoring higher than 10%.